Background-aim: Diabetes mellitus is one of the most prevalent diseases worldwide. According to the ADA 2020 guidelines, individuals with unstable glycemic control should be monitored every three months by measuring glycated hemoglobin (HbA1c). The aim of this study was to evaluate the demand adequacy for HbA1c in the monitoring of patients with diabetes mellitus with a highly unstable glycemic control.
Methods: Retrospective observational study (2016-2019). All HbA1c tests from individuals ≥18 years requested by hospital physicians were considered.Highly unstable glycemic control was defined as HbA1c≥10.0%, and their monitoring was classified as: (if>3months) and if no further HbA1c measurement was performed by the laboratory.For individuals classified as , medical records were reviewed and further re-classified as: [1] due to patient's responsibility, [2] attributable to the requesting physician, [3] monitored by POCT, [4] unfeasibility of monitoring or [5] referral outside our area for follow-up.
Results: During the assessed period, 1,156 patients had an HbA1c value≥10.0%. 67.5% of them were monitored either in the clinical laboratory or as POCT (33.7% optimal monitoring), whereas 21.0% patients were not monitored due to preventable situations.
Conclusion: Lack of monitoring due to physician's reasons or patient's responsibility highlights the urgent need for an improvement.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941057 | PMC |
Surg Innov
December 2024
LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
Background: Intraportal pancreatic islet transplantation is a treatment option for patients with severe beta cell failure and unstable glycemic control. However, this procedure is associated with loss of beta cells after intrahepatic transplantation. Islet delivery devices (IDDs) implanted at extrahepatic sites may support engraftment and improve survival of pancreatic islets.
View Article and Find Full Text PDFHeliyon
November 2024
Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, No. 1 Dongjiaomin Lane, Dongcheng District, Beijing, 100730, PR China.
Cureus
October 2024
Community Medicine, Madha Medical College and Research Institute, Chennai, IND.
Trials
October 2024
KITE Research Institute, University Health Network, University of Toronto, Toronto, Canada.
J Diabetes Sci Technol
October 2024
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!